2020
Longitudinal analyses reveal immunological misfiring in severe COVID-19
Lucas C, Wong P, Klein J, Castro TBR, Silva J, Sundaram M, Ellingson MK, Mao T, Oh JE, Israelow B, Takahashi T, Tokuyama M, Lu P, Venkataraman A, Park A, Mohanty S, Wang H, Wyllie AL, Vogels CBF, Earnest R, Lapidus S, Ott IM, Moore AJ, Muenker MC, Fournier JB, Campbell M, Odio CD, Casanovas-Massana A, Herbst R, Shaw A, Medzhitov R, Schulz W, Grubaugh N, Dela Cruz C, Farhadian S, Ko A, Omer S, Iwasaki A. Longitudinal analyses reveal immunological misfiring in severe COVID-19. Nature 2020, 584: 463-469. PMID: 32717743, PMCID: PMC7477538, DOI: 10.1038/s41586-020-2588-y.Peer-Reviewed Original ResearchConceptsSevere COVID-19Moderate COVID-19Immune signaturesDisease outcomeCOVID-19Disease trajectoriesInterleukin-5Early immune signaturesInnate cell lineagesType 2 effectorsT cell numbersPoor clinical outcomeWorse disease outcomesImmune response profileCoronavirus disease 2019Distinct disease trajectoriesCytokine levelsImmunological correlatesImmune profileClinical outcomesEarly elevationImmune profilingIL-13Immunoglobulin EDisease 2019
2011
Phase II Study of Cetuximab in Combination With Chemoradiation in Patients With Stage IIIA/B Non–Small-Cell Lung Cancer: RTOG 0324
Blumenschein GR, Paulus R, Curran WJ, Robert F, Fossella F, Werner-Wasik M, Herbst RS, Doescher PO, Choy H, Komaki R. Phase II Study of Cetuximab in Combination With Chemoradiation in Patients With Stage IIIA/B Non–Small-Cell Lung Cancer: RTOG 0324. Journal Of Clinical Oncology 2011, 29: 2312-2318. PMID: 21555682, PMCID: PMC3107747, DOI: 10.1200/jco.2010.31.7875.Peer-Reviewed Original ResearchConceptsUnresectable stage III NSCLCEpidermal growth factor receptorStage III NSCLCCombination of cetuximabCell lung cancerOverall survivalLung cancerGrade 4 hematologic toxicityRadiation Therapy Oncology GroupAdequate organ functionCycles of paclitaxelGrade 3 esophagitisGrade 5 eventsZubrod performance statusPhase II studyPrimary end pointCompletion of therapyPhase II trialDoses of paclitaxelPoor clinical outcomeGrowth factor receptorWeekly carboplatinHematologic toxicityII trialAdverse events
2005
Mutations in the Epidermal Growth Factor Receptor and in KRAS Are Predictive and Prognostic Indicators in Patients With Non–Small-Cell Lung Cancer Treated With Chemotherapy Alone and in Combination With Erlotinib
Eberhard DA, Johnson BE, Amler LC, Goddard AD, Heldens SL, Herbst RS, Ince WL, Jänne PA, Januario T, Johnson DH, Klein P, Miller VA, Ostland MA, Ramies DA, Sebisanovic D, Stinson JA, Zhang YR, Seshagiri S, Hillan KJ. Mutations in the Epidermal Growth Factor Receptor and in KRAS Are Predictive and Prognostic Indicators in Patients With Non–Small-Cell Lung Cancer Treated With Chemotherapy Alone and in Combination With Erlotinib. Journal Of Clinical Oncology 2005, 23: 5900-5909. PMID: 16043828, DOI: 10.1200/jco.2005.02.857.Peer-Reviewed Original ResearchMeSH KeywordsAdultAgedAged, 80 and overAntineoplastic Combined Chemotherapy ProtocolsCarboplatinCarcinoma, Non-Small-Cell LungCombined Modality TherapyDNA Mutational AnalysisErbB ReceptorsErlotinib HydrochlorideFemaleGenes, rasHumansLung NeoplasmsMaleMiddle AgedPaclitaxelPlacebosPredictive Value of TestsPrognosisQuinazolinesSurvival AnalysisTreatment OutcomeConceptsRetrospective subset analysisCell lung cancerEGFR mutationsKRAS mutationsLung cancerSubset analysisSingle-agent EGFR inhibitorsEpidermal growth factor receptor (EGFR) mutationsEGFR inhibitorsErlotinib-treated patientsFirst-line chemotherapyAdvanced NSCLC patientsChemotherapy-treated patientsPositive prognostic factorPoor clinical outcomeEGFR inhibitor treatmentImproved response ratesKRAS-mutant NSCLCKRAS exon 2Epidermal growth factor receptorGrowth factor receptorAdvanced NSCLCUntreated patientsNSCLC patientsPrognostic factors
2002
Non-small cell lung cancer clinical trials with trastuzumab: their foundation and preliminary results
Zinner RG, Kim J, Herbst RS. Non-small cell lung cancer clinical trials with trastuzumab: their foundation and preliminary results. Lung Cancer 2002, 37: 17-27. PMID: 12057863, DOI: 10.1016/s0169-5002(02)00035-1.Peer-Reviewed Original ResearchConceptsNon-small cell lung cancerHER2 overexpressionClinical trialsHER2-overexpressing metastatic breast cancerAntibody-dependent cell-mediated cytotoxicityMetastatic breast cancer trialsRandomized phase II trialRecombinant humanized monoclonal antibodyActivity of trastuzumabNSCLC clinical specimensPhase II studyPhase II trialEfficacy of trastuzumabMetastatic breast cancerBreast cancer trialsCell lung cancerCell-mediated cytotoxicityPoor clinical outcomeTreatment of patientsLung cancer clinical trialsHumanized monoclonal antibodyCombination of chemotherapyOverexpression of HER2Cancer clinical trialsDownregulation of HER2